Oculis Holding AG (NASDAQ:OCS) Receives Average Recommendation of “Buy” from Brokerages

Shares of Oculis Holding AG (NASDAQ:OCS) have earned a consensus recommendation of “Buy” from the six analysts that are covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have covered the stock in the last year is $30.17.

A number of research analysts have commented on the stock. Bank of America reduced their price objective on shares of Oculis from $21.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday, June 11th. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Oculis in a research note on Wednesday, August 28th. Robert W. Baird boosted their target price on shares of Oculis from $35.00 to $37.00 and gave the company an “outperform” rating in a research note on Tuesday, June 11th. Finally, Chardan Capital restated a “buy” rating and issued a $30.00 price target on shares of Oculis in a research report on Tuesday, June 11th.

Oculis Stock Performance

Shares of OCS opened at $11.95 on Friday. Oculis has a 52-week low of $9.05 and a 52-week high of $14.47. The company has a quick ratio of 5.27, a current ratio of 5.27 and a debt-to-equity ratio of 0.01. The firm has a market cap of $484.02 million, a price-to-earnings ratio of -6.71 and a beta of 0.30. The business’s 50 day moving average is $11.72 and its two-hundred day moving average is $11.84.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.